“VIDEO: Luminate® Study Shows Equivalence to anti-VEGF with Fewer Injections”

BALTIMORE — Luminate® (ALG-1001) from Allegro Ophthalmics met both its primary and secondary endpoints in a phase 2 trial for the treatment of diabetic macular edema, Peter K. Kaiser, MD, said at the Association for Research in Vision and Ophthalmology meeting here. The integrin antagonist was injected monthly for 3 months and then patients were off treatment for 2 months, compared with five monthly injections of bevacizumab. The study showed Luminate® was non-inferior to the anti-VEGF treatment with fewer injections.

To view the video, please visit Ocular Surgery News“VIDEO: Luminate® Study Shows Equivalence to anti-VEGF with Fewer Injections”